Entera Bio Ltd. Annual Report - How They Did This Year

I’m breaking down Entera Bio’s recent performance into plain English. My goal is to help you understand this company so you can decide if it fits your investment goals.

1. What does this company do?

Entera Bio is a biotech company based in Jerusalem. They focus on a major problem: many life-saving drugs, like proteins and peptides, are destroyed by stomach acid. This forces patients to take painful daily injections.

Entera uses its N-Tab® technology to solve this. Their tablets protect these drugs so the body can be absorbed in the small intestine. By turning injections into pills, they hope to make treatments easier for patients and reach more people with metabolic diseases.

2. Financial health: The "Going Concern" warning

Entera has a long history of losses, with a total deficit of about $184.6 million. In 2023, the company lost $13.7 million, an improvement over the $18.5 million lost in 2022. Revenue was $0.1 million, primarily generated from research services.

The company ended 2023 with $10.6 million in cash. While management believes this will fund operations through late 2026, they carry a "going concern" warning. This indicates a significant doubt about their ability to continue as a business without raising additional capital. They need to secure new funding or partnerships to complete the testing of their main drug, EB613.

3. Their "Star" Project: EB613

Their lead project, EB613, is an oral version of a bone-building hormone. Currently, patients must use daily injections like Eli Lilly’s Forteo®. In early trials, EB613 successfully increased bone density. The company is now preparing for a large Phase 3 study. This project drives almost all of Entera’s value. Success here would prove their technology works and could lead to lucrative deals with major pharmaceutical companies.

4. Major risks: What could go wrong?

Because Entera is still testing its drugs, your investment is a bet on their science. Here are the biggest risks:

• All-or-Nothing: The company’s value depends almost entirely on EB613. If this drug fails in trials, the stock price will likely drop significantly because there are no other advanced products to fall back on.
• Funding and Dilution: To reach the market, Entera needs millions more. Since they are not yet profitable, they may sell more shares to raise cash. This results in more shares issued, which reduces your ownership percentage and the value of your current shares.
• Geopolitical Risk: Their main office is in Jerusalem. The ongoing conflict in the Middle East could disrupt their staff, supply chain, or clinical trials.
• No Dividends: The company has never paid a dividend and does not expect to in the foreseeable future. All capital is directed toward research. If the drugs fail, you could lose your entire investment.

5. Future outlook

Entera has two main goals: raise the money needed for the EB613 Phase 3 trial and find partners for their N-Tab® platform. They are exploring the use of their technology for other applications, such as weight-loss treatments.

Investor Checklist:

• Watch the Cash: Keep an eye on their quarterly cash burn to see how long their runway actually lasts.
• Monitor Partnerships: Any announcement of a partnership with a larger pharmaceutical company would be a major signal of validation for their technology.
• Track Clinical Progress: The outcome of the Phase 3 trial for EB613 is the single most important event for the company's future.

This is a high-risk, high-reward play where profit is still years away. Only invest if you are comfortable with the possibility of total loss in exchange for the potential of a breakthrough in oral drug delivery.